Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology.
1Hyman, Phelps & McNamara, PC, 700 Thirteenth Street, NW Suite 1200, Washington, DC 20005, USA. jgibbs@hpm.com
Expert Review of Molecular Diagnostics
|May 7, 2011
Summary
Government regulation hinders the clinical impact of molecular diagnostics. Revising regulatory approaches, including risk assessment and review criteria, can accelerate the adoption of these important medical tools.
Area of Science:
- Medical Diagnostics
- Regulatory Science
- Health Policy
Background:
- Molecular diagnostics are crucial in modern medicine but face challenges in clinical adoption.
- Current regulatory frameworks may not be optimized for the unique nature of molecular diagnostic technologies.
Purpose of the Study:
- To identify factors limiting the clinical impact of molecular diagnostics.
- To recommend revisions to government regulation to improve the uptake of molecular diagnostics.
Main Methods:
- Analysis of current regulatory systems for molecular diagnostics.
- Identification of key areas for regulatory improvement, including risk assessment and review processes.
Main Results:
- Existing regulatory systems present barriers to molecular diagnostics' clinical utility.
- Predictable and consistent regulatory criteria are essential for advancing adoption.
Conclusions:
- Revisions in risk assessment, review criteria, and product improvement facilitation are recommended.
- Harmonized and predictable regulatory application will enhance the integration of molecular diagnostics into clinical practice.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:24Automated Microbial Diagnostics
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).